-
Mashup Score: 1
Christoffer Gebhardt, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, summarizes the emerging immunotherapeutic treatment landscape for patients with melanoma. The ongoing Phase III INTerpath-001 trial (NCT05933577) employs a combinatory therapeutic approach, using individualized neoantigen therapies (INTs) and pembrolizumab. Rather than using pembrolizumab alone, this immunotherapeutic combination has been evidenced in prior trial data as highly effective, lowering the hazard ratio for distant metastasis free survival. This interview took place at the 2024 American Association for Cancer Research (AACR) in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7KRYSTAL-1: adagrasib with cetuximab in KRAS G12C-mutated CRC - 1 month(s) ago
Scott Kopetz, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses findings from an analysis of the Phase I and II cohorts of the KRYSTAL-1 trial (NCT03785249), which assessed adagrasib with cetuximab in KRAS G12C-mutated colorectal cancer (CRC). Median duration of response, progression-free survival, and overall survival demonstrate clinically meaningful outcomes. Ongoing investigation in the Phase III KRYSTAL-10 trial (NCT04793958) aims to evaluate this combination further as a second-line treatment option for KRASG 12C-mutated CRC. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Developments for TILs and TCR modified cell therapy in solid tumors - 1 month(s) ago
Sebastian Klobuch, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses advances in tumor-infiltrating lymphocytes (TILs) and T cell receptor (TCR) modified cell therapy in oncology. Findings from a Phase III trial (NCT02278887) that compared TILs against checkpoint inhibitors in melanoma demonstrated the superiority of TILs in terms of progression-free survival (PFS), which is further exemplified by the recent approval of lifileucel in melanoma. Additional advances in TCR modified cell therapies include targeting MAGE-A4 in sarcoma. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
🎥@docchristoffer highlights the promising immunotherapeutic landscape for melanoma, discussing the INTerpath-001 trial's combinatory approach with neoantigen therapies and pembrolizumab: ➡️https://t.co/SutBlqoelT⬅️ #AACR24 #ImmunoOnc